Revvity (NYSE:RVTY – Get Free Report) was upgraded by Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.
Other equities research analysts have also issued research reports about the company. Barclays lifted their price objective on Revvity from $95.00 to $105.00 and gave the company an “equal weight” rating in a research note on Thursday, May 7th. Evercore restated an “outperform” rating on shares of Revvity in a research note on Wednesday. Robert W. Baird set a $117.00 price target on Revvity in a report on Wednesday, May 6th. JPMorgan Chase & Co. dropped their price target on Revvity from $96.00 to $90.00 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. Finally, TD Cowen reissued a “buy” rating on shares of Revvity in a report on Wednesday, July 15th. Three research analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $108.36.
Read Our Latest Report on RVTY
Revvity Stock Performance
Revvity (NYSE:RVTY – Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $1.41 EPS for the quarter, beating the consensus estimate of $1.21 by $0.20. The firm had revenue of $711.00 million during the quarter, compared to the consensus estimate of $702.96 million. Revvity had a net margin of 8.16% and a return on equity of 8.34%. The business’s quarterly revenue was down 1.3% compared to the same quarter last year. During the same period last year, the firm earned $1.18 EPS. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, analysts expect that Revvity will post 5.35 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Revvity
Large investors have recently added to or reduced their stakes in the business. Ascentis Independent Advisors bought a new position in Revvity during the 1st quarter worth approximately $29,000. CYBER HORNET ETFs LLC bought a new position in shares of Revvity in the second quarter worth approximately $32,000. MUFG Securities EMEA plc purchased a new position in shares of Revvity in the second quarter worth $34,000. Headlands Technologies LLC bought a new stake in Revvity during the 2nd quarter valued at $49,000. Finally, SJS Investment Consulting Inc. boosted its position in Revvity by 5,210.0% during the 1st quarter. SJS Investment Consulting Inc. now owns 531 shares of the company’s stock valued at $47,000 after buying an additional 521 shares during the period. Hedge funds and other institutional investors own 86.65% of the company’s stock.
Revvity Company Profile
Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.
Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.
Recommended Stories
- Five stocks we like better than Revvity
- Bed Bath & Beyond Renovates: The Neighborhood Blueprint
- These Outperforming Giants Are Boosting Dividends in 2026, With Yields of Up to 6.6%
- Why Analysts Are Bullish on a Stock That’s Down 20%
- SpaceX: Love the Company, But the Stock Is a Harder Call
Receive News & Ratings for Revvity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revvity and related companies with MarketBeat.com's FREE daily email newsletter.
